For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
In the latest session, Abbvie Inc (NYSE: ABBV) closed at $231.8 up 1.00% from its previous closing price of $229.51. In other words, the price has increased by $1.00 from its previous closing price. On the day, 6.89 million shares were traded. ABBV stock price reached its highest trading level at $234.08 during the session, while it also had its lowest trading level at $230.31.
Ratios:
For a deeper understanding of Abbvie Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 72.24 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.81. For the most recent quarter (mrq), Quick Ratio is recorded 0.60 and its Current Ratio is at 0.72.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on November 13, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $280.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 22 ’25 when Richard A. Gonzalez bought 62,755 shares for $210.84 per share.
Richard A. Gonzalez bought 90,000 shares of ABBV for $18,993,948 on Aug 21 ’25. On Aug 12 ’25, another insider, SALEKI-GERHARDT AZITA, who serves as the EVP, CHIEF OPERATIONS OFFICER of the company, sold 42,370 shares for $198.42 each. As a result, the insider received 8,407,055 and left with 177,292 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 409679757312 and an Enterprise Value of 472900763648. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 174.90, and their Forward P/E ratio for the next fiscal year is 16.23. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 10.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.87. Its current Enterprise Value per Revenue stands at 7.929 whereas that against EBITDA is 16.02.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.34, which has changed by 0.253605 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $244.81, while it has fallen to a 52-week low of $164.39. The 50-Day Moving Average of the stock is 1.98%, while the 200-Day Moving Average is calculated to be 13.90%.
Shares Statistics:
For the past three months, ABBV has traded an average of 5.78M shares per day and 6821680 over the past ten days. A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.12% of the company’s shares, while institutions hold 74.64% stake in the company. Shares short for ABBV as of 1763078400 were 18724102 with a Short Ratio of 3.27, compared to 1760486400 on 18080904. Therefore, it implies a Short% of Shares Outstanding of 18724102 and a Short% of Float of 1.06.
Dividends & Splits
According to the company, the forward annual dividend rate for ABBV is 6.56, from 6.56 in the trailing year. Against a Trailing Annual Dividend Yield of 0.028582633. The stock’s 5-year Average Dividend Yield is 3.78.
Earnings Estimates
. The current rating of Abbvie Inc (ABBV) is the result of assessments by 19.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $3.05, with high estimates of $3.3 and low estimates of $2.84.
Analysts are recommending an EPS of between $10.83 and $10.5 for the fiscal current year, implying an average EPS of $10.64. EPS for the following year is $14.24, with 29.0 analysts recommending between $15.43 and $13.01.
Revenue Estimates
A total of 18 analysts believe the company’s revenue will be $16.4B this quarter.It ranges from a high estimate of $17.01B to a low estimate of $16.23B. As of . The current estimate, Abbvie Inc’s year-ago sales were $15.1BFor the next quarter, 18 analysts are estimating revenue of $14.71B. There is a high estimate of $15.2B for the next quarter, whereas the lowest estimate is $14.45B.
A total of 28 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $61.55B, while the lowest revenue estimate was $60.5B, resulting in an average revenue estimate of $60.93B. In the same quarter a year ago, actual revenue was $56.33BBased on 28 analysts’ estimates, the company’s revenue will be $66.62B in the next fiscal year. The high estimate is $68.67B and the low estimate is $65.31B.
